September 23, 2016
First clinical trial to study GLP-1 receptor agonist and SGLT-2 inhibitor combination shows positive results
Experts have speculated that combination GLP-1 receptor agonist and SGLT-2 inhibitor therapy may have synergistic, beneficial effects in the treatment of type 2 diabetes. Now there are data to support this, as results of DURATION-8, the first clinical trial to study the combination as an addition to standard-of-care therapy, were recently announced at the European Association for the Study of Diabetes (EASD) 2016 Annual Meeting and published in the Lancet Diabetes and Endocrinology. Continue reading GLP-1 Receptor Agonists and SGLT-2 Inhibitors: A Dynamic Duo?
One year after FDA approval, are PCSK9 inhibitors living up to expectations?
It’s been about 1 year since the two currently available PCSK9 inhibitors, evolocumab and alirocumab, received US FDA approval. (Bococizumab is still completing phase 3 studies.) Uptake, as most in the healthcare community know, has been slow, largely due to the cost associated with the two therapies.
The US FDA recently approved a monthly single-dose administration option for evolocumab. The system consists of a hands-free device which is designed to provide 420 mg of evolocumab in a single dose and allows patients the freedom of being able to continue with moderate physical activity such as walking, reaching, and bending. The cost is expected to remain similar to twice weekly dosing, and given how new it is, it remains to be seen what kind of impact on clinical practice it will have. Continue reading PCSK9 Inhibitors: 1 Year After Approval
Boston, July 22, 2016––The Cardiometabolic Health Congress has announced 5 Keynote presentations have been scheduled for the 11th Annual CMHC, taking place October 5-8, 2016, at the Sheraton in Boston, MA. The 3 ½-day event has become the largest US-based, multidisciplinary conference focused solely on the prevention, diagnosis, and management of cardiovascular and metabolic diseases.
The increased number of Keynotes for this year’s Annual Meeting will address the growing areas of cardiometabolic disease management and are as follows: Continue reading Keynotes Announced for 11th Annual CMHC!
Despite the well-known fact poor nutrition is a major contributing risk factor for chronic diseases, medical schools are still failing to adequately prepare healthcare professionals for nutrition challenges in clinical practice.
It has become a well known fact that poor nutrition and lifestyle choices play a large role in the development of most chronic conditions, including cardiovascular and metabolic diseases – and cardiometabolic conditions such as diabetes and obesity continue to accelerate at an alarming pace. Yet, the teaching of nutrition in most US medical schools has been recognized for decades as being inadequate. How can healthcare professionals (HCPs) effectively treat their patients without proper education to recognize and treat the nutritional root causes? Continue reading Medical Schools Are Still Largely Ignoring Nutrition Education, Leaving HCPs to Take Their Own Initiative
Theories abound on what’s driving the cardiovascular benefits seen in EMPA-REG, as an FDA advisory panel votes to support a claim of CV risk reduction on the SGLT-2 inhibitor empagliflozin’s label.
An advisory panel to the US FDA has voted, albeit narrowly, to allow the claim that treatment with the SGLT-2 inhibitor epagliflozin reduces the risk of cardiovascular death in patients with type 2 diabetes. Results of EMPA-REG, which were published last year, showed that the drug reduced cardiovascular death by 38% and reduced the combined risk of cardiac death, non-fatal myocardial infarction, and non-fatal stroke by 14%. The potential mechanisms by which empagliflozin works to reduce this cardiovascular risk are still not known, however, and were the focus of discussion at the recent ADA 2016 Scientific Sessions.
Continue reading Are We Any Closer to Understanding What’s Driving the Cardiovascular Benefits Seen in EMPA-REG?
Updated guidelines strive for obesity to be treated as a chronic condition
The obesity epidemic shows no signs of slowing, with an estimated 640 million people worldwide now considered obese. According to the CDC, every 2 of 3 adults are overweight or obese. Recently, the American Association of Clinical Endocrinologists (AACE), who declared obesity a disease in 2012, released evidence-based management guidelines that recommend obesity be approached as a chronic medical condition. Their rationale for the update? “Obesity medicine lacks comprehensive and evidence-based guidelines that are translatable to real-world clinical care of patients with obesity,” said AACE Obesity Scientific Committee Chair W. Timothy Garvey, MD.
Continue reading Will New AACE Guidelines Help Obesity to be Taken More Seriously?
The Cardiometabolic Health Congress launched in October 2006 in Boston and since then has grown to become the largest US-based, multidisciplinary conference addressing cardiometabolic disease prevention and management through an integrated approach to education. Now in its 11th year, CMHC Boston is held each October and attended by 1300+ mid to advanced level healthcare professionals seeking real-world solutions to integrate directly into their clinical practices. The goal of the CMHC is to improve patient outcomes through early identification and intervention strategies for patients with, or at risk of developing, cardiovascular and metabolic disease.
Continue reading History of the Cardiometabolic Health Congress (CMHC)